ERBB2 and breast carcinoma: Goetz et al. have investigated PDX formation from 113 breast cancer patients, reporting an overall take rate of 27.4%, but with remarkable differences among various breast cancer subtypes: 51% in TNBC, 26% in HER2+, 5% in luminal B, and 0% in luminal A tumors [447].